S. Korea to shorten licensing review period new drugs on rare diseases by 25 days

Korean health regulators will shorten licensing review period from 115 days to 90 days for investigational bio drugs to treat severe or rare disease or pandemic disease with no available alternative, [전체본문 2020-09-10 11:17:00Z]